Personalizing therapy for colorectal cancer

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 1, 2014, Pages 139-144

  Wong, Ashley ^a   Ma, Brigette B Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Colorectal Cancer; Gene Signatures; KRAS Mutation

Indexed keywords

ADENOSINE TRIPHOSPHATE; BEVACIZUMAB; CETUXIMAB; DIHYDROPYRIMIDINE DEHYDROGENASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FLUOROURACIL; GLUCURONOSYLTRANSFERASE 1A1; IMMUNOGLOBULIN G1; IRINOTECAN; K RAS PROTEIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PLACENTAL GROWTH FACTOR; RAF PROTEIN; REGORAFENIB; SOMATOMEDIN B; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; WNT1 PROTEIN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; COLON CANCER; COLORECTAL CANCER; DRUG METABOLISM; GENE TARGETING; GENETIC ASSOCIATION; GENETIC CODE; GENETIC VARIABILITY; HUMAN; METASTATIC COLORECTAL CANCER; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RECTUM CANCER; SIGNAL TRANSDUCTION; SOMATIC MUTATION; SYSTEMIC THERAPY; COLORECTAL NEOPLASMS; GENETICS; MOLECULAR MEDICINE; PROCEDURES;

COLORECTAL NEOPLASMS; HUMANS; MOLECULAR MEDICINE; PRECISION MEDICINE;

EID: 84890213381     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.08.040     Document Type: Article

References (41)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337. Cancer Genome Atlas Network.
3. Simon I., Roepman P., Schlicker A., et al. Association of colorectal cancer intrinsic subtypes with prognosis, chemotherapy response, deficient mismatch repair, and epithelial to mesenchymal transition (EMT): Proc ASCO GI meeting. JClin Oncol 2013, (Suppl 34). abstr 333.
4. Kelley R.K., Venook A.P. Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?. Clin Colorectal Cancer 2011, 10:73-80.
5. Kopetz S., Freitas D., Calabrich A.F., et al. Adjuvant chemotherapy for stage II colon cancer. Oncology (Williston Park) 2008, 22:260-270.
6. Ogino S., Chan A.T., Fuchs C.S., et al. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 2010, 60:397-411.
7. van Engeland M., Derks S., Smits K.M., et al. Colorectal cancer epigenetics: complex simplicity. JClin Oncol 2011, 29:1382-1391.
8. Yamauchi M., Morikawa T., Kuchiba A., et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012, 61:847-854.
9. Soreide K., Nedrebo B.S., Knapp J.C., et al. Evolving molecular classification by genomic and proteomic biomarkers in colorectal cancer: potential implications for the surgical oncologist. Surg Oncol 2009, 18:31-50.
10. Van Cutsem E., Kohne C.H., Hitre E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. NEngl J Med 2009, 360:1408-1417.
11. Douillard J.Y., Siena S., Cassidy J., et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. JClin Oncol 2010, 28:4697-4705.
12. Jonker D.J., O'Callaghan C.J., Karapetis C.S., et al. Cetuximab for the treatment of colorectal cancer. NEngl J Med 2007, 357:2040-2048.
13. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. JClin Oncol 2007, 25:1658-1664.
14. Sobrero A.F., Maurel J., Fehrenbacher L., et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. JClin Oncol 2008, 26:2311-2319.
15. Peeters M., Price T.J., Cervantes A., et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. JClin Oncol 2010, 28:4706-4713.
16. Bardelli A., Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. JClin Oncol 2010, 28:1254-1261.
17. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. JClin Oncol 2008, 26:1626-1634.
18. Lievre A., Bachet J.B., Le Corre D., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66:3992-3995.
19. Di Fiore F., Blanchard F., Charbonnier F., et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007, 96:1166-1169.
20. De Roock W., De Vriendt V., Normanno N., et al. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011, 12:594-603.
21. Price T.J., Hardingham J.E., Lee C.K., et al. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. JClin Oncol 2011, 29:2675-2682.
22. De Roock W., Claes B., Bernasconi D., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2011, 11:753-762.
23. Van Cutsem E., Dicato M., Arber N., et al. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. Ann Oncol 2010, 21(Suppl 6):vi1-vi10.
24. Stewart C.F., Panetta J.C., O'Shaughnessy M.A., et al. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. JClin Oncol 2007, 25:2594-2600.
25. Innocenti F., Kroetz D.L., Schuetz E., et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. JClin Oncol 2009, 27:2604-2614.
26. Kelley R.K., Van Bebber S.L., Phillips K.A., et al. Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. JNatl Compr Canc Netw 2011, 9:13-25.
27. Adam R., Wicherts D.A., de Haas R.J., et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?. JClin Oncol 2009, 27:1829-1835.
28. Folprecht G., Gruenberger T., Bechstein W.O., et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010, 11:38-47.
29. Wong R., Cunningham D., Barbachano Y., et al. Amulticentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol 2010, 22:2042-2048.
30. Ye L.C., Liu T.S., Ren L., et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. JClin Oncol 2013, 31:1931-1938.
31. Colon and rectum 2010, 173-260. Springer, New York. 7th ed. S.G. Edge, D.R. Byrd, C.C. Compton (Eds.).
32. Hurwitz H.F., Novotny L., Cartwright W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. NEngl J Med 2004, 350:2335-2342.
33. Arnold D., Bennouna J., Sastre J., et al. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: results of a randomized phase III intergroup study (TML study)-Proc ASCO Annual Meeting. JClin Oncol 2012, 30(18 Suppl).
34. Tournigand C., Scheithauer W., Lledo G., et al. Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients (pts) with metastatic colorectal cancer (mCRC): efficacy and safety results of the International GERCOR DREAM phase III trial-Proc ASCO Annual Meeting. JClin Oncol 2012, 30(18 Suppl).
35. Van Cutsem E., Tabernero J., Lakomy R., et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. JClin Oncol 2013, 30:3499-3506.
36. Grothey A., Van Cutsem E., Sobrero A., et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2012, 381:303-312.
37. Morris E.J., Maughan N.J., Forman D., et al. Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? the need for high quality pathology. Gut 2007, 56:1419-1425.
38. Le Voyer T.E., Sigurdson E.R., Hanlon A.L., et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. JClin Oncol 2003, 21:2912-2919.
39. Sargent D.J., Marsoni S., Monges G., et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. JClin Oncol 2010, 28:3219-3226.
40. Hutchins G., Southward K., Handley K., et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. JClin Oncol 2012, 29:1261-1270.
41. Gerlinger M., Rowan A.J., Horswell S., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. NEngl J Med 2012, 366:883-892.